# OnCo record abarelix (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/abarelix/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "abarelix" ;
  schema:name "Abarelix"@en ;
  schema:description "Abarelix was the first GnRH antagonist for prostate cancer, approved in the United States in 2003 for men who could not take agonists, but allergic reactions restricted it and it was withdrawn from the US market in 2005; it remained available in Germany."@en ;
  schema:url <https://onco.cc/drugs/abarelix/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Abarelix> ;
  schema:citation <https://en.wikipedia.org/wiki/Abarelix>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201180> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "GnRH antagonist peptide, intramuscular depot" ;
  schema:alternateName "Plenaxis" ;
  onco:approval "US 2003: Advanced symptomatic prostate cancer in men who cannot take GnRH agonists (restricted programme)" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/gnrhr/> ;
  onco:drugs <https://onco.cc/drugs/degarelix/>, <https://onco.cc/drugs/leuprolide/> ;
  onco:trials <https://onco.cc/trials/nct00841113/>, <https://onco.cc/trials/nct00100243/> .